After acquiring Raleigh-based Salix Pharmaceuticals for $10 billion a year-and-a-half ago, Valeant Pharmaceuticals International (NYSE: VRX) is considering selling it off, the Wall Street Journal reported Tuesday.
Citing sources familiar with the matter, the WSJ reported that Takeda Pharmaceutical Co. of Japan is in “advanced talks” to buy Salix for “$8.5 billion in cash and future royalty payments.”
A Salix sale would enable Valeant to pay off debts, according to WSJ, following an accounting…
After acquiring Raleigh-based Salix Pharmaceuticals for $10 billion a year-and-a-half ago, Valeant Pharmaceuticals International (NYSE: VRX) is considering selling it off, the Wall Street Journal reported Tuesday.
Citing sources familiar with the matter, the WSJ reported that Takeda Pharmaceutical Co. of Japan is in “advanced talks” to buy Salix for “$8.5 billion in cash and future royalty payments.”
A Salix sale would enable Valeant to pay off debts, according to WSJ, following an accounting…